Saturday 17 October 2026
Export BSX’s income statement to Excel — free account
Boston Scientific Corporation
BSX Healthcare Medical Devices
Boston Scientific Corporation’s revenue for fiscal 2025 (year ended December 2025) was $20.1 billion, up 19.9% from fiscal 2024. In the quarter to June 2026, revenue grew 7.53%, EPS grew 14.8%, free cash flow grew 13.3% and total debt rose 8.95%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
44.39
0.25
+0.57%
Follow BSX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 15.37% | 14.69% | 12.47% | 12.52% |
+8 more TTM periods Free account |
|
Piotroski F-Score |
7 | 8 | 7 | 6 | |
| 8.47% | 8.44% | 6.98% | 6.91% | ||
ROIC |
6.96% | 6.64% | 6.65% | 6.38% | |
Return on Tangible Assets |
64.81% | 43.60% | 39.21% | 42.94% | |
Average Days of Receivables |
53.01 | 53.60 | 53.20 | 53.34 | |
Free Cash Flow per Share |
2.47 | 2.34 | 2.47 | 2.58 | |
Free Cash Flow |
3,625.00 | 3,475.00 | 3,658.00 | 3,824.00 | |
Capital Expenditures |
(904.00) | (866.00) | (876.00) | (802.00) | |
| Other line items | |||||
Cash ROIC |
9.46% | 9.01% | 9.66% | 10.48% | |
Accounts Receivable Turnover |
7.16 | 7.21 | 7.32 | 7.26 | |
Accounts Payable Turnover |
5.76 | 5.93 | 5.91 | 6.37 | |
Inventory Turnover |
2.07 | 2.13 | 2.16 | 2.14 | |
Average Days of Payables |
71.15 | 65.50 | 67.12 | 60.16 | |
Days of Inventory on Hand |
186.98 | 178.94 | 172.67 | 175.38 | |
Tax Rate |
(0.05) | (0.05) | (0.15) | (0.15) | |
Research and Development Expense of Revenue |
10.25% | 10.31% | 10.22% | 10.04% | |
Selling, General and Administrative Expense of Revenue |
34.29% | 34.52% | 34.54% | 34.70% | |
Share Based Compensation of Revenue |
1.52% | 1.49% | 1.49% | 1.53% | |
Interest Coverage |
11.43 | 10.61 | 10.35 | 10.23 | |
Operating CF/Net income |
1.23 | 1.22 | 1.56 | 1.66 | |
Depreciation/Fixed assets |
0.34 | 0.35 | 0.35 | 0.40 | |
Capex/Depreciation |
(0.64) | (0.60) | (0.62) | (0.53) | |
Revenue per Share |
14.28 | 13.88 | 13.56 | 13.06 | |
Operating CF per Share |
3.08 | 2.92 | 3.06 | 3.12 | |
Capex per Share |
(0.61) | (0.58) | (0.59) | (0.54) | |
Capex to Sales |
0.04 | 0.04 | 0.04 | 0.04 |
Columns are period end dates